- Chemotherapy-induced peripheral neuropathy is nerve damage causing tingling, pain, numbness and motor problems, usually starting in the toes.
- Symptoms can appear immediately and worsen through the course; they may be temporary or lifelong.
- Treatment ranges from anticonvulsants and painkillers to dose reduction or changing/stopping the drug.
- Reporting symptoms early is critical; supportive measures include movement, massage and immune support.
What is neuropathy (after chemotherapy)?
Peripheral neuropathy describes pain, discomfort and other symptoms arising from damage to the peripheral nerves. The peripheral nervous system carries signals from the brain (and spinal cord) throughout the body. Any damage to this communication can affect the hands, feet, skin, muscles, joints and other systems. Chemotherapy can damage these nerves.
Symptoms of neuropathy after chemotherapy
Neuropathy after chemotherapy usually affects both sides of the body equally. Symptoms most often begin in the toes but can move to the feet and hands, ranging from mild to very severe. Common symptoms include: tingling or a pins-and-needles sensation; sharp, stabbing pain; burning or shock-like sensations; loss of sensation or complete numbness; problems with fine motor skills (writing, pressing buttons); dropping objects; excessive sensitivity to touch; balance and coordination problems; and temperature sensitivity. Severe peripheral neuropathy can cause serious complications including blood-pressure changes, heart-rhythm disturbances, injury from falls, and organ dysfunction.
What causes neuropathy after chemotherapy
Chemotherapy drugs are powerful and act on the whole body, so some drugs can damage your peripheral nervous system. It is hard to say exactly which drug will cause a particular reaction. Other contributing factors include autoimmune disorders and spinal-cord damage.
How long does neuropathy after chemotherapy last?
Symptoms can appear immediately after starting chemotherapy and worsen as the course continues. For some people neuropathy is a temporary problem lasting only days or weeks; for others it can last months or years, and may even become a lifelong problem — more likely if you have other health conditions.
How is neuropathy after chemotherapy treated?
Once the oncologist establishes that chemotherapy is causing your neuropathy, they monitor whether symptoms worsen. Symptoms may be treated with: hormones to reduce inflammation, topical creams, anticonvulsant drugs to calm the nerves, strong painkillers, antidepressants, and massage. If symptoms do not pass or worsen, the oncologist may reduce the chemotherapy dose, change the drug, postpone the course, or stop chemotherapy. It is very important to communicate with your doctor, reporting sensations and new symptoms, and to mention any other health problems.
How to support recovery
You can help yourself considerably by doing the following: Lentinan supplements are used before, during and after chemotherapy; breathing exercises (look into the Wim Hof method); massage; and sport (do not underestimate it). Concentrated mushroom-polysaccharide formulas are studied for their role in supporting the immune system during oncological treatment.
Concentrated mushroom polysaccharides are studied for supporting the immune system during oncological treatment, alongside conventional neuropathy management.
Lentinan AXT by Zenius Labs™ →It is peripheral neuropathy — pain, discomfort and other symptoms from damage to peripheral nerves caused by chemotherapy. It usually affects both sides equally, often beginning in the toes and moving to the feet and hands.
Common symptoms include tingling or pins-and-needles, sharp stabbing or burning pain, numbness, problems with fine motor skills, dropping objects, sensitivity to touch and temperature, and balance problems. Severe cases can cause blood-pressure changes, heart-rhythm disturbances and falls.
Symptoms can appear immediately and worsen as the course continues. For some people it lasts only days or weeks; for others, months, years, or even a lifelong problem — more likely with other health conditions.
Treatment may include anti-inflammatory hormones, topical creams, anticonvulsants, strong painkillers, antidepressants and massage. If symptoms persist, the oncologist may reduce the dose, change the drug, postpone or stop chemotherapy. Reporting symptoms early is important.
- Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. PubMed
- Clinical practice guidelines on integrative therapies during and after breast cancer treatment. PubMed
- Peripheral Neuropathy: A Review. PubMed
- MP-101 – a novel drug for prevention and treatment of peripheral neuropathy symptoms. CORDIS
- Wang H et al. Efficacy of biological response modifier lentinan with chemotherapy for advanced cancer: a meta-analysis. Cancer medicine. 2017. PubMed
- Wang Y et al. Systematic review and meta-analysis on the efficacy and safety of Injectable Lentinan combined with chemotherapy in the treatment of gastric cancer. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2024. PubMed
- Yin X et al. A meta-analysis of lentinan injection combined with chemotherapy in the treatment of nonsmall cell lung cancer. Indian journal of cancer. 2015. PubMed
- Zhang D et al. Network Meta-Analysis of Chinese Herbal Injections Plus the FOLFOX Regimen for the Treatment of Colorectal Cancer in China. Integrative cancer therapies. 2019. PubMed
- Zhao C et al. Lentinan combined with cisplatin for the treatment of non-small cell lung cancer. Medicine. 2021. PubMed
- Wang Y et al. Investigation on the efficiency of lentinan for injection combining cisplatin on treating malignant pleural effusion based on systematic review and meta-analysis. Medicine. 2024. PubMed
- Sun M et al. Lentinan reduces tumor progression by enhancing gemcitabine chemotherapy in urothelial bladder cancer. Surgical oncology. 2015. PubMed
- Kataoka H et al. Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life. Hepato-gastroenterology. 2009. PubMed
- Huo X et al. Lentinan Enhances the Function of Oxaliplatin on the Esophageal Tumors by Persuading Immunogenic Cell Death. Computational and mathematical methods in medicine. 2022. PubMed
- Wang JL et al. Combination therapy with lentinan improves outcomes in patients with esophageal carcinoma. Molecular medicine reports. 2012. PubMed
- Wang Z et al. Apaf1 nanoLuc biosensors identified lentinan as a potent synergizer of cisplatin in targeting hepatocellular carcinoma cells. Biochemical and biophysical research communications. 2021. PubMed
- Yagi M et al. [Provision for adverse effect of S-1 containing chemotherapy in patients with advanced digestive cancer–combination with superfine dispersed lentinan]. Gan to kagaku ryoho. Cancer & chemotherapy. 2010. PubMed
- Yoshino S et al. Improvement of QOL and prognosis by treatment of superfine dispersed lentinan in patients with advanced gastric cancer. Hepato-gastroenterology. 2010. PubMed
- Zhen C et al. Comprehensive mechanisms and advanced delivery strategies of lentinan in antitumor therapy: A review. Colloids and surfaces. B, Biointerfaces. 2026. PubMed
- Oba K et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer immunology, immunotherapy : CII. 2007. PubMed
- Pilkington K et al. Coriolus (Trametes) versicolor mushroom to reduce adverse effects from chemotherapy or radiotherapy in people with colorectal cancer. The Cochrane database of systematic reviews. 2022. PubMed
- Ito G et al. Correlation between efficacy of PSK postoperative adjuvant immunochemotherapy for gastric cancer and expression of MHC class I. Experimental and therapeutic medicine. 2012. PubMed
- Tanaka H et al. Impact of adjuvant immunochemotherapy using protein-bound polysaccharide-K on overall survival of patients with gastric cancer. Anticancer research. 2012. PubMed
- Gringhuis SI et al. Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-kappaB activation through Raf-1 and Syk. Nature immunology. 2009. PubMed
- Lu H et al. TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011. PubMed
- Amino M et al. [Studies on the effect of lentinan on human immune system. II. In vivo effect on NK activity, MLR induced killer activity and PHA induced blastic response of lymphocytes in cancer patients]. Gan to kagaku ryoho. Cancer & chemotherapy. 1983. PubMed
- Patchen ML et al. In vitro and in vivo hematopoietic activities of Betafectin PGG-glucan. Experimental hematology. 1998. PubMed
- Hamano K et al. The preoperative administration of lentinan ameliorated the impairment of natural killer activity after cardiopulmonary bypass. International journal of immunopharmacology. 1999. PubMed
- Shalaby AM et al. The possible role of astaxanthin in cisplatin-induced nephrotoxicity in rats: interplay between non-coding RNA, redox state, inflammation, and ferroptosis: a histological, immunohistochemical, and biochemical study. Journal of molecular histology. 2026. PubMed
- Krestinin R et al. Astaxanthin Protects Against H(2)O(2)- and Doxorubicin-Induced Cardiotoxicity in H9c2 Rat Myocardial Cells. Life (Basel, Switzerland). 2024. PubMed
- El-Agamy SE et al. Astaxanthin Ameliorates Doxorubicin-Induced Cognitive Impairment (Chemobrain) in Experimental Rat Model: Impact on Oxidative, Inflammatory, and Apoptotic Machineries. Molecular neurobiology. 2018. PubMed
- Bonet IJM et al. Second messengers mediating high-molecular-weight hyaluronan-induced antihyperalgesia in rats with chemotherapy-induced peripheral neuropathy. Pain. 2022. PubMed
- Laderian A et al. Hepatoprotective effect of astaxanthin against cholestasis liver fibrosis induced by bile duct ligation in adult Wistar rats. Journal of biochemical and molecular toxicology. 2024. PubMed
- Yu X et al. Astaxanthin Ameliorates Skeletal Muscle Atrophy in Mice With Cancer Cachexia. Nutrition and cancer. 2024. PubMed
- Saini RK et al. Dietary carotenoids in cancer chemoprevention and chemotherapy: A review of emerging evidence. Pharmacological research. 2020. PubMed
- Ma Y et al. Can polysaccharide K improve therapeutic efficacy and safety in gastrointestinal cancer? a systematic review and network meta-analysis. Oncotarget. 2017. PubMed
- Cotte AK et al. Lysophosphatidylcholine acyltransferase 2-mediated lipid droplet production supports colorectal cancer chemoresistance. Nature communications. 2018. PubMed
- Zou X et al. Radioprotective effect of edible and medicinal mushrooms against ionizing radiation: Components, potential mechanisms, and applications. Food research international (Ottawa, Ont.). 2025. PubMed